Dramatic Therapeutic Response to Dabrafenib Plus Trametinib in BRAF V600E Mutated Papillary Craniopharyngiomas: A Case Report and Literature Review

Dramatic Therapeutic Response to Dabrafenib Plus Trametinib in BRAF V600E Mutated Papillary Craniopharyngiomas: A Case Report and Literature Review

BackgroundCraniopharyngioma is a rare intracranial tumor, with a high morbidity rate due to its common refractiveness to conventional treatments. BRAF V600E mutation has recently been identified as the principal oncogenic molecular driver of papillary craniopharyngiomas (PCP), one of the two main va...

Full description

Bibliographic Details
Main Authors: Morena Fasano, Carminia Maria Della Corte, Marianna Caterino, Mario Pirozzi, Raffaele Rauso, Teresa Troiani, Giulia Martini, Stefania Napolitano, Floriana Morgillo, Fortunato Ciardiello
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-01-01
Series:Frontiers in Medicine
Subjects:
craniopharyngioma
BRAF
BRAF mutation V600E
targeted
dabrafenib
trametinib
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2021.652005/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2021.652005/full

Similar Items